

Welcome to Today's Webinar: Talking with Patients about the Fall COVID-19, Flu, and RSV Vaccine Season




October 18, 2023
12:00PM – 1:00PM



Questions

During today's webinar, please use the Q&A panel to ask your questions so CDPH subject matter experts can respond directly.



Resource links will be dropped into, “Chat”

Housekeeping

Reminder to Attendees:



Today's session is being recorded. Access today's slides and archived presentations at: [COVID-19 Crucial Conversations](#)




If you have post-webinar questions, please email diane.evans@cdph.ca.gov

Webinar Objectives

Participants will learn:

- The current rates and impact of flu, RSV, and COVID-19 in our communities
- Strategies to discuss and increase vaccine acceptance
- How to effectively counsel patients on the risk and spread of respiratory viruses during the holiday season



Agenda: Wednesday, October 18, 2023

No.	Item	Speaker(s)	Time (PM)
1	Welcome and Poll	Diane Evans (CDPH)	12:00 – 12:05
2	Talking with Patients about the Fall COVID-19, Flu, and RSV Vaccine Season	Ilan Shapiro, MD	12:05 – 12:40
Questions and Answers			12:40 – 12:55
3	Poll and Resources	Diane Evans (CDPH)	12:55 – 1:00
Thank you!			

Poll: CDPH appreciates your feedback!

How confident are you in your ability to effectively discuss the COVID-19, Flu, and RSV vaccines with patients?

- Very confident
- Confident
- Somewhat confident
- Slightly confident
- Not confident




Talking with Patients about the Fall COVID-19, Flu, and RSV Season


Ilan Shapiro, MD, MBA, FAAP, FACHE



Disclosure



Disclosure



Boss Team

About AltaMed...



Founded in **1969**, AltaMed Health Services Corporation is a network of federally qualified health centers (FQHCs)



+60 service sites (Los Angeles & Orange Counties)



+1 million encounters for primary care, behavioral health, dental services, senior care, and other social services for **+490K** unique patients.



Approximately **86% – 97%** of our patient population self-identifying as Latino.

Objectives

1. What is new for 2023-2024 season
2. How to create conversations about RSV, Influenza and COVID-19 protection
3. What do we know about the RSV Vaccines and who can get them
4. Understand why we need to make a case for Influenza and COVID-19 vaccines
5. Learn a process to have conversations around vaccination



What has changed?

- 1) COVID-19
- 2) Influenza
- 3) RSV



Influenza

2023-2024 Influenza Season

RSV, Influenza and SARS-CoV-2 may co-circulate and people may become co-infected.

Late summer and increasing cases

Receiving the flu and COVID-19 vaccines is the most effective way to prevent infection.

At-Risk Community Members

- Adults 65 years old and older
- Elderly people living in long-term care facilities
- Adults with chronic health conditions.
- Pregnant women
- Young children less than 5-years-old

If you need to have a
focus laser aim..



Influenza: Why is it Important?


- Influenza and pneumonia were responsible for a total of 41,917 deaths
- The death rate per 100,000 population was 12.6, indicating the severity of the impact of these illnesses
- When compared to other causes of death, influenza, and pneumonia ranked 13th in terms of their frequency as the primary cause of death
- This data underscores the significance of addressing and managing these respiratory diseases to safeguard public health
- **What does this mean?** It is still an important infection that needs to be addressed. Hygiene, preventive physical measures (surfaces), detection, vaccination, and treatment play an important role.

Influenza: Why is it important?

Season	Symptomatic Illnesses		Medical Visits		Hospitalizations		Deaths	
	Estimate	95% U I	Estimate	95% U I	Estimate	95% U I	Estimate	95% U I
2018-2019	29,000,000	(25,000,000 – 40,000,000)	17,000,000	(11,500,000 – 18,500,000)	380,000	(300,000 – 66,000)	28,000	(19,000 – 97,000)
2019-2020	36,000,000	(29,000,000 – 71,000,000)	16,000,000	(13,000,000 – 32,000,000)	390,000	(313,000 – 750,000)	25,000	(18,000 – 79,000)
Preliminary estimates*								
2021-2022*	9,000,000	(7,700,000 – 15,000,000)	4,000,000	(3,600,000 – ,300,000)	100,000	(82,000 – 176,000)	5,000	(3,700 – 20,000)


**Estimates are not available for the 2021-2022 flu season due to minimal influenza activity

Influenza




Influenza

**Figure 2. Flu Vaccination Coverage by State,
Children 6 months—17 years, United States, 2022–23 Season**




Data Source: National Immunization Survey-Flu (NIS-Flu)
 Error bars represent 95% confidence intervals around the estimates.

Why are you important for this?




Influenza



Influenza

Figure 7. Flu Vaccination Coverage by State, Adults 18 years and older, United States, 2022–23 Season



Data Source: Behavioral Risk Factor Surveillance System (BRFSS)

Error bars represent 95% confidence intervals around the estimates.

Coverage estimates for Kentucky, North Dakota, and Pennsylvania were 35.8%, 38.2%, and 53.5%, respectively, but are excluded from the figure because these estimates represent vaccinations only through November 2022.

Influenza

When to get vaccinated:

NOW NOW NOW NOW NOW NOW
NOW NOW NOW NOW NOW NOW
NOW NOW NOW NOW NOW NOW
NOW NOW NOW NOW NOW NOW
NOW NOW NOW NOW NOW NOW
NOW NOW NOW NOW NOW NOW
NOW NOW NOW NOW NOW NOW
NOW NOW NOW NOW NOW NOW
NOW NOW NOW NOW NOW NOW
NOW NOW NOW NOW NOW NOW
NOW NOW NOW NOW NOW NOW
NOW NOW NOW NOW NOW NOW
NOW NOW NOW NOW NOW NOW
NOW NOW NOW NOW NOW NOW
NOW NOW NOW NOW NOW NOW
NOW NOW NOW NOW NOW NOW



Influenza: Who?

Everyone 6 months and older in the United States should get an influenza (flu) vaccine every season with rare exceptions.

- **< 65 y/o** : ANY ONE IS GOOD!
 - MANY OPTIONS: [Influenza Vaccination: A Summary for Clinicians](#)
 - Just remember that with pediatric patients they will need the first season 2 doses (1 month after)
- **> 65 y/o**
 - [Fluzone High-Dose Quadrivalent vaccine](#), [Flublok Quadrivalent vaccine](#) and [Fluad Quadrivalent adjuvanted flu vaccine](#).


COVID: What's New?

United States of America Situation

Line graph icon | Area graph icon | Daily | Weekly


103,436,829

confirmed cases



1,127,152

deaths



Source: World Health Organization

▨ Data may be incomplete for the current day or week.

COVID: What's New?


Daily infections [↗](#)

[Trend](#) [Compare](#) [Map](#)

Reported cases are the number of people reported to be infected with COVID-19 each day.

Estimated **Reported cases**

Scenario **Projection**



COVID-19: What's New?

Vaccines

- Critical to decreasing hospitalization and mortality
- 2023-2024 updated COVID-19 vaccine

Treatments

- Access to antivirals, combined with hybrid immunity, can improve outcomes this season

COVID-19: Who and When?

- a) 2 Months after your last vaccine
- b) After recovery from COVID-19
- c) Anybody after 6 months of age



COVID-19: Who and When?



COVID-19: Still a lot of misinformation out there



Infodemiology.com is a new resource to help you monitor and respond to trending vaccine-related narratives.


INSIGHTS — OCTOBER 13, 2023

NFL stars prompt widespread vaccine conversation and calls for debate

Several weeks ago, NFL star Travis Kelce was featured in a Pfizer commercial for the updated COVID-19 vaccine. Media personalities claimed Kelce was “leading people to their slaughter” by promoting the vaccine. Another NFL star, Aaron Rodgers, mocked Kelce on a popular football show, advocating against the COVID-19 vaccine and calling Kelce “Mr. Pfizer.” Kelce addressed the comments, stating that he stands by promoting the vaccine. Rodgers has publicly called for Kelce to debate him about the safety of the COVID-19 vaccine on television. Social media users are sharing widespread criticism of each player.

- Be prepared to continue answering questions about safety and efficacy.
- Talking points may emphasize that the benefits of vaccination outweigh the risks for all age groups.
- Say that staying up to date on COVID-19 vaccines prevents severe illness and death.

RSV: The new thing in town



Why RSV?

- Respiratory Syncytial Virus (RSV) **poses a significant health burden** in the United States each year, particularly affecting vulnerable populations like children under 5 years old and adults aged 65 and older.
- The data shows that RSV leads to approximately **2.1 million outpatient visits among children under 5**, indicating the widespread impact of the virus on this age group.
- Additionally, RSV causes between **58,000 to 80,000 hospitalizations in children under 5 years old**, underlining the severity of the illness.


Why RSV?

- For adults aged 65 years and older, RSV is responsible for **60,000 to 160,000 hospitalizations annually**, signifying the importance of monitoring and managing the virus in this age group.
- Furthermore, RSV-related deaths in this older population range from 6,000 to 10,000, underscoring the **potential lethality of the virus among older adults**.

Why RSV?

- While RSV-related deaths are relatively rare among children under 5 years old, they still account for 100 to 300 fatalities annually, highlighting the **significance of preventive measures and early detection** to protect young children from severe outcomes.

RSV: The new thing in town



Why RSV?



Vaccines?


For adults: This year, for the first time, we have an RSV vaccines for adults older than 60 (Arexvy or Abrysvo) under shared clinical decision making

For the pediatric population: previously, there was only a monoclonal antibody used for high-risk patients

FDA has approved and CDC recommends Beyfortus (nirsevimab-alip) for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in neonates and infants younger than 8 months born during or entering their first RSV season, and in high-risk children 8 through 19 months in their 2nd RSV season

Conversation Methodology

aka Answering Tough Questions/Having Tough Conversations



To address patients concerns related to myths and misinformation, use the 3-5-3 method.



3 Steps to Initiating/Continuing Conversations

1

Ask and listen to the answer

“What do you think about the vaccine?”

“Why do you feel that way?”

“What concerns do you have about the vaccine?”

2

Create an alignment of safety

“I would be scared too. Let’s do what’s safe here.”

“We both want what's safest for you.”

3

Find common goals

“What reasons would motivate you to get vaccinated?”

Find their personally motivating reason.

Key Messages

1

It is okay to have questions.



Key Messages

2

It is okay to get Influenza and COVID protection at the same time.



Key Messages

3

We are starting the season



Key Messages

4

1 week of sickness?



Key Messages

5

Have questions? Please ask.

I am glad you want to know more. Ultimately, the choice is yours. Today or when you're ready, go to myturn.ca.gov or text your zip code to GETVAX or VACUNA to get your vaccine.



3 Steps to End the Conversation

1

Acknowledge their agency and personal choice

“I want you to get vaccinated today, but ultimately it’s your choice.”

“I’m here as a resource to help you.”

2

Keep lines of communication open

Trust is a journey. Give folks a way to reach you that you are comfortable with as they consider their decision.

3


Offer to find a vaccine

Offer myturn.ca.gov or have them text their zip code to GETVAX or VACUNA to find a vaccine location in their neighborhood.



Questions

During today's webinar, please use the Q&A panel to ask your questions so CDPH subject matter experts can respond directly.



Resource links will be dropped into, “Chat”

Poll & Resources

Diane Evans, CDPH

Poll: CDPH appreciates your feedback!

How confident are you in your ability to effectively discuss the COVID-19, Flu, and RSV vaccines with patients?

- Very confident
- Confident
- Somewhat confident
- Slightly confident
- Not confident




- New resource for clinicians and other health care providers.
- **Infodemiology Brief:** Monthly newsletter with reports on trending health narratives and helpful resources. [Sign up](#).
- **Insights & Dashboards:** Weekly misinformation updates and national and state dashboards with real-time media data.
- **Infodemiology Training Program:** Learn how to identify and respond to trending health narratives. [Join the waitlist for the October launch](#).




Curated **infodemiology** resources and tools to deliver better **care**

From the latest research to tailored trainings for doctors and other health care providers, we provide actionable content to help navigate today's information landscape. Explore our resources.




INFODEMOLOGY BRIEF

Reports providing trending health narratives, recommendations, and helpful resources to improve patient care.



REAL-TIME INSIGHTS

Weekly updates on health misinformation trends across the country, plus state dashboards with real-time media data.



TRAINING RESOURCES

Short, flexible training modules designed to improve patient care in today's complex information landscape.


New COVID-19 vaccine education videos

New COVID-19 education videos tailored for different populations.

General population


Older adults

Young adult BIPOC



Testing and developing mRNA vaccines

1990 1989 1988 1987



With the virus still spreading,
older adults are at high risk for having
a severe COVID-19 infection.



Available for sharing from [Public Good News](#), [ThisIsOurShot](#), and [VacunateYa](#).
Videos for immune compromised individuals coming soon.

CDPH Provider Webinars and Trainings

Week of October 16, 2023

	Monday 10/16	Tuesday 10/17	Wednesday 10/18	Thursday 10/19	Friday 10/20
Live Webinars and Training	Nirsevimab Updates and Implementation Guidance and Considerations for RSV 12:00 pm – 1:00 pm	American Academy of Pediatrics (AAP) Webinar: Nirsevimab Implementation Strategies in Outpatient Pediatric Practices 5:00 pm – 6:00 pm	Current Issues in Immunization Webinar (CIIW): Clinical Update on the 2023 Respiratory Virus Season 9:00 am – 10:00 am COVID-19 Crucial Conversations Webinar: Talking with Patients about the Fall COVID-19, Flu, and RSV Season 12:00 pm – 1:00 pm	Bi-Weekly State General Fund (SGF) Program Office Hours 11:00 am – 11:30 am	CDPH Immunization Updates for Providers 9:00 am – 10:30 am
View On Demand	<ul style="list-style-type: none"> Intro to My Turn Onboarding (v. 1/4/22) CDPH Weekly Provider Webinars Archived Recordings and Slides 	<ul style="list-style-type: none"> myCAvax Release Notes for LHJs and CDPH Users (Requires myCAvax Login) Latest Features in myCAvax for Providers (Requires myCAvax Login) COVID-19 Crucial Conversations Archived Webinars and Slides 	<ul style="list-style-type: none"> Moderna COVID-19 Vaccine Resources for Providers CDC COVID-19 Vaccine Webinar Series California Immunization Coalition COVID Conversation Series AIM Vaccine Confidence Toolkit Webinar Series 		
Help	<p>Help Desk</p> <p>myCAvax Help Desk Email: mycavax.hd@cdph.ca.gov My Turn Help Desk Email: myturn.clinic.hd@cdph.ca.gov My Turn Onboarding Email: myturnonboarding@cdph.ca.gov</p>		<p>General</p> <p>CDPH Provider Call Center: 1-833-502-1245, 8am-5pm, Mon-Fri Email: providercallcenter@cdph.ca.gov Vaccines: COVID-19 Vaccines Therapeutics: COVID-19 Therapeutics</p>		<p>Mpox</p> <p>Email: stdcb@cdph.ca.gov General Website: Mpox Website Vaccines: Mpox Vaccines Website</p>


Calendar Subject to Change

Last Updated: 10/13/23



Digital Vaccine Record

GET YOUR DIGITAL VACCINE RECORD



Private. Convenient. Secure.


What is a Digital Vaccine Record (DVR)?
Your Digital Vaccine Record (DVR) is an electronic vaccination record from the California Immunization Registry (CAIR) and is an official record of the state of California.

What information does the DVR include?
The DVR has your name, date of birth, vaccination dates, and the vaccines you received.

Where do I access my Digital Vaccine Record?
Visit myvaccinerecord.cdph.ca.gov to access your record. You will need to enter your first and last name, date of birth, and mobile number or email address. You will create a PIN which will be required to obtain your DVR when the link to your record is provided to you.

What digital records can I access from the DVR Portal?
There are two types of records you can access from the DVR Portal:

- **COVID-19 QR code** that (when scanned by a SMART Health Card reader) will display the same information as your paper CDC vaccine card: your name, date of birth, vaccination dates, and vaccines.
- **Record of all your vaccinations** that were reported by pharmacies and healthcare providers to CAIR. Note that your historical vaccinations may not have been reported to CAIR.




For more DVR questions, visit myvaccinerecord.cdph.ca.gov/faq or call 1-833-422-4255 (open M-F 8AM-8PM, SA-SU 8AM-5PM).

California Department of Public Health, Immunization Branch

IMM-1461 (3/9/23)

DVR Fact Sheet

OBTenga SU REGISTRO DIGITAL DE VACUNACIÓN



PRIVADO. COVENIENTE. SEGURO.



Registro Digital de Vacunación (DVR)
Su Registro Digital de Vacunación (DVR, por sus siglas en inglés) es un registro electrónico de vacunación procedente del Registro de Vacunación de California (CAIR, por sus siglas en inglés) y es un registro oficial del estado de California.

¿Qué información incluye el DVR?
El DVR tiene su nombre, fecha de nacimiento, fechas de vacunación y las vacunas que recibió.

¿Dónde accedo mi Registro Digital de Vacunación?
Visite myvaccinerecord.cdph.ca.gov para acceder su registro. Necesita ingresar su primer nombre y apellido, fecha de nacimiento y número de celular o correo electrónico. Necesitará crear un PIN para poder obtener su DVR cuando se le proporcione el enlace a su registro.

¿Qué registros digitales puedo acceder desde el Portal DVR?
Hay dos tipos de registros a los que puede acceder desde el Portal DVR:

- **Código QR de COVID-19** que (cuando es escaneado por un lector de tarjetas SMART Health) mostrará la misma información que su tarjeta de papel de los CDC: su nombre, fecha de nacimiento, fechas de vacunación y las vacunas.
- **Registro de todas las vacunas** que informaron las farmacias y otros proveedores de salud a CAIR. Tome en cuenta que es posible que su historial de vacunación no se haya ingresado a CAIR.



Para más preguntas sobre el DVR, visite myvaccinerecord.cdph.ca.gov/faq-es/ o llame al 1-833-422-4255 (L-V 8AM-8PM, S-D 8AM-5PM).

California Department of Public Health, Immunization Branch

IMM-1461S (3/30/23)

Spanish Version

- To access their DVR, patients should visit the [Digital Vaccine Record \(DVR\) portal](http://myvaccinerecord.cdph.ca.gov) (myvaccinerecord.cdph.ca.gov)
- Flyers are also available in [Arabic](#), [Simplified Chinese](#) and [Traditional Chinese](#), [Korean](#), [Tagalog](#) and [Vietnamese](#).
- The DVR request form is also available in the languages listed above to support easy communication. Records are also printable in these languages! See our [DVR FAQs](#) for more information.

Updated COVID-19 Resources

- **Jump links** to navigate to specific topics
- **Vaccine Ordering & Manufacturer Info** webpage (private & public vaccines)
- **Vaccine Information Statements** to be published this fall; what to do in the interim!
- **Novavax resources** updated for 2023-24 formula!

Novavax (2023-24 COVID-19 Vaccine, Adjuvanted)

- Authorization under EUA for 12Y+: [Fact Sheet for HCPs](#) | [Fact Sheet for Recipients & Caregivers](#) | [Novavax COVID-19 Vaccine \(FDA\)](#)
- Websites: [Manufacturer](#) | CDC Resources (coming soon)

EZIZ A one-stop shop for immunization training and resources.

COVID-19 Vaccine Resources

This landing page provides vaccine-specific resources to support all programs that supply COVID-19 vaccines. Relevant links are still being moved from the former EZIZ/COVID page. Please check back!

Jump To Topic:

- Vaccine Information
- Vaccine Administration
- Communicating with Patients
- Archived Communications

Vaccine Information

- COVID-19 Vaccine Access & Ordering (private and public vaccines)
- Vaccine Ordering & Manufacturer Info (private and public vaccines)
- COVID-19 Vaccine Product Guide | Spanish (Updated 9/20)
- COVID-19 Vaccine Timing Guide (Updated 9/29)
- Vaccine Program Eligibility Guidelines: VFC, VFA, BAP (for Community Health Centers)
- CDC Updated Standing Order Templates for Moderna and Pfizer (CDC)

COVID-19 Vaccine Information Statements (VISs)

Currently, providers are required by law to provide EUA fact sheets to vaccine recipients or their caregivers for all uses of Novavax and when Moderna or Pfizer vaccines are given to children 6 months through 11 years of age. For recipients who are 12 or older receiving Pfizer or Moderna vaccine, a provider may use the manufacturer's package insert (COMIRNATY Patient Package Insert or SPIKEVAX Patient Package Insert), written FAQs, or any other document (including provider-produced information materials) to inform patients about the benefits and risks of that vaccine. CDC will publish a Vaccine Information Statement this fall. See CDC Vaccine Information Statements Page.

Pfizer-BioNTech (2023-24 COVID-19 Vaccine, mRNA)

- Approval of Comirnaty for 12Y+: Provider Letter | Package Insert (not currently available) | COMIRNATY (FDA)
- Authorization under EUA for 6M-11Y: Provider Letter | Fact Sheet for HCPs | Fact Sheet for Recipients & Caregivers | Pfizer-BioNTech COVID-19 Vaccine (FDA)
- Dry Ice Safety
- Websites: [Manufacturer](#) | [CDC Resources](#)

Moderna (2023-24 COVID-19 Vaccine, mRNA)

- Approval of Spikevax for 12Y+: Provider Letter | Package Insert (not currently available) | Patient Package Insert | FDA page
- Authorization under EUA for 6M-11Y: Provider Letter | Fact Sheet for HCPs | Fact Sheet for Recipients & Caregivers | Moderna COVID-19 Vaccine (FDA)
- Websites: [Manufacturer](#) | [CDC Resources](#)

Novavax (2023-24 COVID-19 Vaccine, Adjuvanted)

- Authorization under EUA for 12Y+: [Fact Sheet for HCPs](#) | [Fact Sheet for Recipients & Caregivers](#) | [Novavax COVID-19 Vaccine \(FDA\)](#)
- Expiry Checker
- Websites: [Manufacturer](#) | [CDC Resources](#) (coming soon)

General Resources

- CDC Recommends Updated COVID-19 Vaccine for Fall/Winter Virus Season (CDC)
- Updated mRNA COVID-19 Vaccines to Better Protect Against Currently Circulating Variants (FDA)
- Updated COVID-19 Vaccines for Use in the United States Beginning in Fall 2023 (FDA)
- Resources for the Fall Respiratory Illness Season (COVID-19, Flu and RSV) (FDA)

Vaccine Administration

- Interim Clinical Considerations for Use of COVID-19 Vaccines (CDC)
- ACIP Recommended Immunization Schedules: Child and Adolescent | Adult (CDC)
- Coadministration of COVID-19 Vaccines (CDC) | Coadministration Tips (graphic)

COVID-19 Vaccine Provider FAQs

- Answers to provider questions
- Updated 10/13/2023
- Currently in its 133rd iteration!

 **Updated** **Q: Which COVID-19 vaccines are recommended for use by the CDC?**

A: In addition to the Moderna and Pfizer vaccines, CDC's [Interim Clinical Considerations for the Use of COVID-19 Vaccines](#) was recently updated to include Novavax information.

 **New** **Q: When will the updated Novavax COVID-19 vaccine be available for ordering?**

A: The updated Novavax COVID-19 vaccine is now available for ordering through myCAvax for Bridge Access Program (BAP) providers and through myVFCvaccines for Vaccines for Children (VFC) providers.

COVID-19 Vaccine FAQs v.133_10.13.23 1


COVID-19 Vaccine FAQs

For Providers administering COVID-19 vaccine.
Providers may also visit [EZIZ COVID-19 Resources](#) for information and updates.

Directions: [Click on a category to be directed to related FAQs.](#)

Contents

New and Updated FAQs.....	2
Vaccine Program Management	3
Vaccine Administration.....	3
Vaccine Storage & Handling.....	5
Reporting.....	6
Communication Resources	6



COVID-19 Vaccine Support


Provider Call Center

Dedicated to medical providers and Local Health Departments in California, specifically addressing questions about State program requirements, enrollment, and vaccine distribution.

- For myCAVax Help Desk inquiries: myCAVax.hd@cdph.ca.gov
- For My Turn Clinic Help Desk inquiries: MyTurn.Clinic.HD@cdph.ca.gov
- For all other inquiries: providercallcenter@cdph.ca.gov
- Phone: (833) 502-1245, Monday through Friday from 8AM–5PM

myCAVax

- Virtual Assistant resolves many questions but will direct you to the Provider Call Center queue for live assistance!
- Knowledge Center houses key job aids and videos that are updated every release. Once logged in, you can access job aids from the myCAVax homepage (or at various places throughout the system) using the links as shown below.  Need help? View our jobs aids in the Knowledge Center, or contact us.



Updated COVID-19 Vaccine Timing Guide 2023-2024

COVID-19 Vaccine Timing 2023-24 –Routine Schedule

Age*	Vaccine	If unvaccinated:	If had any prior doses, give 2023-24 doses:
6 months–4 years†	Pfizer–Infant/Toddler	1st Dose → 3-8 weeks** → 2nd Dose → ≥8 weeks → 3rd Dose	If 1 prior dose, then: 3-8* weeks 1 ≥8 weeks 2 If ≥2 prior doses, then: ≥8 weeks 1
	Moderna–Pediatric*	1st Dose → 4-8 weeks** → 2nd Dose	If 1 prior dose, then: 4-8 weeks 1 If ≥2 prior doses then: ≥8 weeks 1
5–11 years	Moderna–Pediatric*	1 Dose	If 1 or more prior doses (of any of the brands), then*: ≥2 months 2023-24 Formulation: Moderna/Pfizer
	Pfizer–Pediatric	1 Dose	
12+ years	Pfizer–Adol/Adult (Comirnaty)	1 Dose	If 1 or more prior doses (of any of the brands), then*: ≥2 months 2023-24 Formulation: Moderna/Pfizer/Novavax
	Moderna–Adol/Adult (Spikevax)	1 Dose	
	Novavax	1st Dose → 3-8 weeks** → 2nd Dose	

* See [CDC recommendations](#) for children transitioning from a younger to older age group
 † Children 6 months – 4 years should receive the same brand of the updated vaccine as the prior doses they received.
 ** An 8-week interval may be preferable for some people, especially for males 12-39 years.
 ‡ All Moderna doses 6 months – 11 years are 0.25 mL (25 mcg).
 † Janssen (J & J) vaccine has been deauthorized. Follow schedule for 12+ years for any prior doses.

View [Interim Clinical Considerations for Use of COVID-19 Vaccines](#) for details. Schedule is subject to change.



COVID-19 Vaccine Timing 2023-24 if Moderately/Severely Immunocompromised

Age	Vaccine	If unvaccinated:	If had any prior doses give 2023-24 doses:
6 months–4 years	Pfizer Infant/Toddler	1st Dose → 3 weeks → 2nd Dose → ≥8 weeks → 3rd Dose → ≥2 months → Optional Dose*	1 prior dose: 3 w 1 ≥8 w 2 ≥2 m Optional Dose* ≥2 prior doses: ≥8 w 1
	Moderna–Pediatric	1st Dose → 4 weeks → 2nd Dose → ≥4 weeks → 3rd Dose → ≥2 months → Optional Dose*	1 prior dose: 4 w 1 ≥4 w 2 ≥2 m Optional Dose* 2 prior doses: ≥4 w 1 ≥3 prior doses**: ≥8 w 1
5–11 years	Moderna–Pediatric	1st Dose → 4 weeks → 2nd Dose → ≥4 weeks → 3rd Dose → ≥2 months → Optional Dose* Moderna/Pfizer	≥3 prior doses** (for ages 5+ yrs, Pfizer dose is also OK): ≥8 w 1
	Pfizer–Pediatric	1st Dose → 3 weeks → 2nd Dose → ≥4 weeks → 3rd Dose → ≥2 months → Optional Dose* Moderna/Pfizer	1 prior dose: 3 w 1 ≥4 w 2 ≥2 m Optional Dose* 2 prior doses: ≥4 w 1 ≥3 prior doses**: ≥8 w 1
12+ years	Pfizer–Adol/Adult (Comirnaty)	1st Dose → 3 weeks → 2nd Dose → ≥4 weeks → 3rd Dose → ≥2 months → Optional Dose* Moderna/Pfizer/Novavax	1 prior dose: 3 w 1 ≥4 w 2 ≥2 m Optional Dose* 2 prior doses: ≥4 w 1 ≥3 prior doses**: ≥8 w 1
	Moderna–Adol/Adult (Spikevax)	1st Dose → 4 weeks → 2nd Dose → ≥4 weeks → 3rd Dose → ≥2 months → Optional Dose* Moderna/Pfizer/Novavax	1 prior dose: 4 w 1 ≥4 w 2 ≥2 m Optional Dose* 2 prior doses: ≥4 w 1 ≥3 prior doses**: ≥8 w 1
	Novavax	1st Dose → 3 weeks → 2nd Dose → ≥2 months → Optional Dose* Moderna/Pfizer/Novavax	≥1 prior doses**: ≥2 m 1
	Optional Dose* Moderna/Pfizer/Novavax		5-11 yrs: Moderna/Pfizer 12+ yrs: Moderna/Pfizer/Novavax

* An optional dose may be given ≥2 months after the last dose. Further doses may be given at the healthcare provider's discretion. See [Table 2](#) for vial and dosage.
 ** Ages 5-11 years may be given Moderna or Pfizer after ≥3 prior doses. Ages 12+ years may be given Moderna, Pfizer, or Novavax.

COVID-19 Vaccine Product Guide - Updated

COVID-19 Vaccine Product Guide



Check vaccine labels and [FDA materials](#) before use to avoid mix-ups.
EUA fact sheets supersede info on vials and carton. Refer to [CDC Product Guide](#) for more information.

	Pfizer		
	Infant/Toddler 6 months–4 years	Pediatric 5–11 years	Comirnaty 12+ years
	2023-24 Formula	2023-24 Formula	2023-24 Formula

Packaging	Yellow Cap	Blue Cap	Gray Cap
Doses Per Vial	3 doses	1 dose	1 dose
Carton Size	30 doses	10 doses	10 doses
NDC-Unit of Use (vial)	59267-4315-01	59267-4331-01	00069-2362-01
CVX Code	308	310	309
CPT Code	91318	91319	91320
Program Availability	VFC	VFC	VFC, BAP
Min. Standard Order*	30 doses	10 doses	10 doses

Storage Limits Before Puncture: Label vaccine with expiration and use-by dates.			
ULT	Until expiration date at -90°C to -60°C (-130°F to -76°F)		
Thermal Shipper			
Freezer			
Refrigerator	Up to 10 weeks at 2° to 8°C (36°F to 46°F). Write the date on carton—not to exceed expiration.		
Expiration Date	Check the label or Pfizer product website .		

Administration			
Diluent (supplied)	1.1 mL per vial	Do not dilute	Do not dilute
Dose Volume & Dose	0.3 mL 3 mcg dose	0.3 mL 10 mcg dose	0.3 mL 30 mcg dose
Refrigerator Thaw Time (Do not refreeze)	2 hours in carton (2° to 8°C/36°F to 46°F)		
Room Temp Thaw Time (Do not refreeze)	Vial: 30 minutes at up to 25°C (77°F)		
Total Time at Room Temp	Up to 12 hours (including thaw time) at 8°C to 25°C (46°F to 77°F)		
Storage Limits After Puncture (Multi-dose vials): Record puncture and use-by time on vial label.			
Use-By Limit (Discard Time After 1st Puncture)	Discard 12 hours after dilution. Keep at 2°C to 25°C (35°F to 77°F)	N/A	N/A

* Orders for privately purchased vaccines may have different order minimums.

COVID-19 Vaccine Product Guide



Check vaccine labels and [FDA materials](#) before use to avoid mix-ups.
EUA fact sheets supersede info on vials and carton. Refer to [CDC Product Guide](#) for more information.

	Moderna		
	Pediatric 6 months– 11 years	Spikevax 12+ years	Spikevax 12+ years
	2023-24 Product	2023-24 Product	2023-24 Product

Packaging	Dark Blue Cap	Dark Blue Cap	Syringe
Doses Per Vial	1 dose	1 dose	1 dose
Carton Size	10 doses	10 doses	10 doses
NDC-Unit of Use (vial)	80777-0287-07	80777-0102-04	80777-0102-01
CVX Code	311	312	312
CPT Code	91321	91322	91322
Program Availability	VFC	VFC, BAP	N/A
Min. Standard Order*	10 doses	10 doses	N/A

Storage Limits Before Puncture: Label vaccine with expiration and use-by dates.			
ULT			
Thermal Shipper			
Freezer	Until expiration at -50°C to -15°C (-58°F to 5°F)		
Refrigerator	Up to 30 days (not to exceed expiration date) at 2–8°C (36–46°F)		
Expiration Date	Check Moderna product website or QR code.		

Administration			
Diluent (supplied)	Do not dilute		
Dose Volume & Dose	0.25 mL 25 mcg	0.5 mL 50 mcg	0.5 mL 50 mcg
Refrigerator Thaw Time (Do not refreeze)	45 minutes for single dose vial or 1 hour for syringe at 2°C to 8°C (36°F to 46°F). Let stand at room temp for 15 min before administering.		
Room Temp Thaw Time (Do not refreeze)	15 minutes for single dose vial or 45 minutes for syringe at 15° to 25°C (59° to 77°F)		
Total Time at Room Temp	Store up to 24 hours at 8°C to 25°C (46°F to 77°F)		
Storage Limits After Puncture (Multi-dose vials) Record use-by time on vial.			
Use-By Limit (Discard Time After 1st Puncture)	N/A. Discard after single use.		

* Orders for privately purchased vaccines may have different order minimums.

COVID-19 Vaccine Product Guide



Do Not Use Deauthorized Products:

Use only COVID-19 vaccine products updated for 2023-24.

Pfizer					
Infant/Toddler 6 months–4 years		Pediatric 5–11 years		Adol/Adult 12+ years	
2021 Monovalent	Bivalent	2021 Monovalent	Bivalent	2021 Monovalent	Bivalent

Moderna				
Infant/Toddler 6 months– 5 years	Infant/Toddler 6 months– 5 years	6 months+	Pediatric 6–11 years	Adol/Adult 12+ years
2021 Monovalent	Bivalent	Bivalent	2021 Monovalent	2021 Monovalent

Janssen (J&J)
Adult 18+ years
2021 Monovalent

Novavax
Primary 12+ yrs Booster 18+
2022 Monovalent

Immunization Timing 2023


Suggested schedule to meet recommendations on time. [Refer to web version.](#)

Birth
HepB¹
RSV² (age: 0-8 months)

6 months – 18+ years	
COVID-19 vaccine(s)⁶	Flu vaccine, every fall⁷

Age	Interval from previous dose	Age	Interval from previous dose	Age	Interval from previous dose	Age	Interval from previous dose	Age	Interval from previous dose	Age	Interval from previous dose
2 months		4 months	1-2 months	6 months	1-2 months	12 months		15 months	6-12 months	18 months	6-18 months
DTaP (Diphtheria, Tetanus, Pertussis)		DTaP		DTaP		HepA⁸ (age: 12-23 months)		DTaP¹²		HepA	
Polio (IPV)		Polio (IPV)	1-2 months	Polio age: 6-18 months	1-14 months	MMR^{8,9,10} (ages 12-15 months)					
HepB³ (age: 1-2 months)	1-2 months after birth dose	HepB³ if 1st dose given at 2 months	1-2 months	HepB³ (age: 6-18 months)	2-12 months and ≥4 months after 1st dose	Var¹⁰ (age: 12-15 months)					
Hib (Hib meningitis)		Hib	1-2 months	Hib⁵	1-2 months	Hib (age: 12-15 months)	2-8 months				
PCV (Pneumo)		PCV	1-2 months	PCV	1-2 months	PCV¹¹ (age: 12-15 months)	6-8 weeks				
RV⁴ (Rotavirus)		RV⁴	4-10 weeks	RV⁴ if RotaTeq used for doses 1 or 2	4-10 weeks						

Age 4-6 years	DTaP Polio (IPV) MMR^{9,10} Varicella¹⁰
Age 11-12 years	Tdap HPV¹³ (2 doses, can start at age 9) MenACWY (MCV4)
Age 16 years	MenACWY (MCV4) MenB¹⁴



California Department of Public Health, Immunization Branch • EZIZ.org IMM-395 (10/23)

This is a suggested schedule. For alternatives and details, including additional recommendations for high-risk children, consult the Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2023.

New RSV Resources Webpage

EZIZ
A one-stop shop for immunization training and resources.

ENHANCED BY Google

RSV

RSV Immunization Resources

General Information for Providers

- RSV Immunization Information (CDC)
- RSV Immunization FAQs
- 2023 RSV Health Alert (CDC)
- RSV Trends in the United States (CDC)

Infants and Children

- Nirsevimab (Beyfortus) Guide to Prevent Severe RSV in Infants and Toddlers
- Nirsevimab Guidance (CDC)
- Clinical Guidance to Prevent RSV Disease in Infants Webinar (CDC)
- Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023
- ACIP and AAP Recommendations for the Use of the Monoclonal Antibody Nirsevimab for the Prevention of RSV Disease (8/15/23)
- Nirsevimab Frequently Asked Questions (AAP)
- Beyfortus (Nirsevimab) Product Insert (FDA)
- CDC recommends new vaccine to help protect babies against severe respiratory syncytial virus (RSV) illness after birth (Press Release)

Pregnancy

- Clinical Guidance: RSV Vaccination for Pregnant People (CDC)
- Maternal RSV Vaccination Practice Advisory (ACOG)

Older Adults

- Clinical Guidance: RSV Vaccination for 60+ (CDC)
- Shared Clinical Decision-Making Guidance Flyer for RSV Vaccine (CDC)
- Frequently Asked Questions About RSV Vaccine for Adults (CDC)
- Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023 (CDC)
- New RSV Vaccines for Adults: General Information and Clinical Guidance (CDC Webinar 8/30/23)
- Product Inserts for ABRYVVO and AREVXY (FDA)

Patient Resources

- RSV Communications Toolkit
- Fall-Winter 2023 Immunizations Infographic
- RSV Vaccine Information Statements (VIS)
- Nirsevimab Immunization Information Statement (CDC)

Home
Vaccine Programs
Vaccine Management
Storage Units
Temperature Monitoring
EZIZ Training
Job Aids & Resources

Contact VFC
Phone: 1-877-243-8832
Business hours:
Monday - Thursday: 9 am - 4:30 pm
Friday: 9 am - 4 pm
Fax: 1-877-329-9832

- Find a VFC field representative in your area
- Find other VFC provider offices in your area
- Send us your comments at MyVFCvaccines@cdph.ca.gov

Sign up to receive EZIZ news and VFC letters via email

Frequently Asked Questions

About EZIZ | www.getimmunizedca.org | View CDPH's privacy policy

- [RSV FAQs](#)
- [Nirsevimab Timing Guide](#)
- CDC Clinical Recommendations
- Patient Resources

Stay Healthy this Virus Season

6 Tips for Staying Healthy this Virus Season

Reduce your risk of catching and spreading respiratory viruses like flu, COVID-19 and RSV.

Stay Up to Date on Vaccines
Vaccines are the best protection against severe illness. Visit [MyTurn.ca.gov](https://myturn.ca.gov) to schedule your vaccines or contact your health care provider.

- **Flu and COVID-19 vaccines** are available for everyone 6 months and older.
- **RSV immunizations** are available for infants and some young children, pregnant people and adults 60 years and older.



Stay Home if You're Sick
Stay home and away from others if you have any symptoms of [flu](#), [COVID-19](#), or [RSV](#).

Test and Treat
[Test for COVID-19](#) and flu if you have symptoms. If you test positive, contact your health care provider and ask about medications. Medications work best when started right after symptoms begin. Learn more about [COVID-19 treatments](#).

Consider Wearing a Mask
Consider [wearing a mask](#) in public indoor or crowded spaces especially if you or your family is at [higher-risk for severe illness](#).

Wash Your Hands
Wash your hands often, with soap and warm water, for at least 20 seconds. If soap and water are not available, use a hand sanitizer with at least 60% alcohol.

Cover Your Cough or Sneeze
Cough or sneeze into your elbow, arm, or a disposable tissue. Make sure to wash your hands or sanitize and dispose of your tissue after.









Scan the QR code to see interactive links on this flyer



September 2023 • © 2023, California Department of Public Health

FALL-WINTER 2023-24 IMMUNIZATIONS



	Who is eligible?	What immunizations are recommended?	When should I get it?
Influenza 	6 months and older	Flu vaccines target 4 strains of flu and are available as a shot or nasal spray. Flu vaccine prevents millions of illnesses and flu-related doctor's visits each year.	September or October are ideal, but catching up later can still help.
COVID-19 	6 months and older	Updated COVID-19 vaccines target the Omicron XBB strain to protect against COVID-19 this fall and winter	Get it now to help protect against severe disease (if at least two months since your last COVID-19 shot).
RSV (Pregnant Persons) 	Pregnant persons during weeks 32-36 of pregnancy	RSV vaccine to reduce the risk of severe RSV disease in infants (baby will receive protection that lasts for months after birth)	Recommended from September to January to help protect your baby during RSV season
OR			
RSV (Infants and Toddlers) 	All infants from birth to 8 months and children 8-19 months at high risk of severe RSV disease	Immunization contains preventive antibodies that help fight RSV infections and protect children from getting very sick.	Before or during RSV season, usually October-March
RSV (Older Adults) 	60 years and older	RSV vaccine to protect older adults against RSV disease	Available now - Talk with your doctor to determine if vaccination is right for you.

Where to get vaccinated?

- Contact your doctor or local pharmacy. Influenza and COVID-19 vaccines continue to be free for most people through their private, Medi-Cal or Medicare insurance plans.
- Check with your insurance on timing of RSV immunization coverage.
- You can receive influenza, COVID-19 and/or RSV immunizations during the same visit.
- Adults without health insurance can get no cost COVID-19 vaccine at many pharmacies and clinics participating in the [Bridge Access Program](#). Visit vaccines.gov to find the nearest location.
- Children who are Medi-Cal eligible, American Indian/Alaskan Native, uninsured and underinsured may get no cost vaccines through the [Vaccines for Children Program](#).

Thanks to Katelyn Jetelina, PhD, MPH and Caitlin Rivers, PhD, MPH for allowing CDPH to adapt this resource.

California Department of Public Health | Immunization Branch IMM-1481 (10/23)

Upcoming Webinar Opportunities

CDPH Immunization Updates for Providers

Next session: Friday, October 20, 2023

9AM – 10:30AM



Special Thanks to
Today's Presenter:
Ilan Shapiro, MD

Webinar Planning & Support:

Billie Dawn Greenblatt, Michael Fortunka,
Charles Roberts, Diane Evans, Tyler Janzen,
and Laura Lagunez-Ndereba

